Covered, compounding. A 1.04% yield on a $0.66 quarterly dividend, raised in August 2026 from $0.60 — a 10% increase — is covered at a 25.3% trailing payout. Sleep-apnea device and software revenue grew 8.6% year over year in the latest reported quarter, and the payout leaves most earnings retained for growth.
Key risk: GLP-1 and device competition — weight-loss drugs and rival sleep devices could slow new-patient growth; the low payout gives room, but the growth story, not the dividend, would slow first.
Changes if: Payout pushes well past 25.3% or the annual raise stops. A low payout that stops growing is a different card.
- ✓Payout-coverage check: 25.3% trailing payout — $2.64 indicated against trailing earnings.
- ✓Yield check: 1.04% indicated — $0.66/qtr × 4 at the $252.86 close on Oct. 23, 2026. Earned operating dividend, not return of capital.
- ✓Dividend growth check: Raised August 2026, $0.60 to $0.66 (+10%), paid Sep. 24, 2026; 13 years of growth counted on the trailing basis.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.